CA3188891A1 - Fused imidazole derivative, preparation method therefor, and medical use thereof - Google Patents
Fused imidazole derivative, preparation method therefor, and medical use thereofInfo
- Publication number
- CA3188891A1 CA3188891A1 CA3188891A CA3188891A CA3188891A1 CA 3188891 A1 CA3188891 A1 CA 3188891A1 CA 3188891 A CA3188891 A CA 3188891A CA 3188891 A CA3188891 A CA 3188891A CA 3188891 A1 CA3188891 A1 CA 3188891A1
- Authority
- CA
- Canada
- Prior art keywords
- general formula
- compound
- mixture
- pharmaceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010905693 | 2020-09-01 | ||
| CN202010905693.4 | 2020-09-01 | ||
| CN202010984336 | 2020-09-18 | ||
| CN202010984336.1 | 2020-09-18 | ||
| CN202011124085 | 2020-10-20 | ||
| CN202011124085.6 | 2020-10-20 | ||
| CN202011253077.1 | 2020-11-11 | ||
| CN202011253077 | 2020-11-11 | ||
| CN202011407911 | 2020-12-04 | ||
| CN202011407911.8 | 2020-12-04 | ||
| CN202011627733.X | 2020-12-31 | ||
| CN202011627733 | 2020-12-31 | ||
| PCT/CN2021/115915 WO2022007979A1 (zh) | 2020-09-01 | 2021-09-01 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188891A1 true CA3188891A1 (en) | 2022-01-13 |
Family
ID=79552285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188891A Pending CA3188891A1 (en) | 2020-09-01 | 2021-09-01 | Fused imidazole derivative, preparation method therefor, and medical use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US12227499B2 (https=) |
| EP (2) | EP4706757A3 (https=) |
| JP (2) | JP7812052B2 (https=) |
| KR (1) | KR20230058660A (https=) |
| CN (5) | CN119930603A (https=) |
| AU (1) | AU2021306414B2 (https=) |
| CA (1) | CA3188891A1 (https=) |
| DK (1) | DK4209490T3 (https=) |
| FI (1) | FI4209490T3 (https=) |
| MX (1) | MX2023001980A (https=) |
| PT (1) | PT4209490T (https=) |
| TW (1) | TW202220985A (https=) |
| WO (1) | WO2022007979A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202206429A (zh) * | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| MX2022015026A (es) * | 2020-06-04 | 2023-01-04 | Hangzhou Sciwind Biosciences Co Ltd | Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4204415A4 (en) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| CR20230330A (es) * | 2021-01-28 | 2023-11-15 | Carmot Therapeutics Inc | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2023011539A1 (zh) * | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
| CA3229524A1 (en) * | 2021-08-24 | 2023-02-03 | Qinghua MAO | Imidazocyclic compound and application thereof |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250049778A1 (en) * | 2021-12-23 | 2025-02-13 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of glp-1 receptor agonist and preparation method therefor |
| EP4455141B1 (en) * | 2021-12-23 | 2026-03-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystalline form of a glp-1 receptor agonist for the treatment of diabetes |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| WO2023246833A1 (zh) * | 2022-06-23 | 2023-12-28 | 西藏海思科制药有限公司 | 一种五并五元环衍生物的药物组合物及其在医药上的应用 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| WO2024131869A1 (en) * | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN116102555A (zh) * | 2022-12-23 | 2023-05-12 | 华中药业股份有限公司 | 咪唑并芳杂基类衍生物及其应用 |
| TW202434574A (zh) * | 2023-02-02 | 2024-09-01 | 大陸商江蘇豪森藥業集團有限公司 | 一種環烯類化合物的鹽、晶型及其製備方法和應用 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025007843A1 (zh) * | 2023-07-03 | 2025-01-09 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型前药化合物或稠环化合物 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025148954A1 (zh) * | 2024-01-09 | 2025-07-17 | 山东盛迪医药有限公司 | 一种glp-1r激动剂药物组合物及其应用 |
| WO2025162257A1 (zh) * | 2024-02-01 | 2025-08-07 | 上海森辉医药有限公司 | 制备苯并二氧杂环或其盐方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2025252201A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏豪森药业集团有限公司 | 一种环烯类衍生物的制备方法 |
| WO2026017039A1 (zh) * | 2024-07-15 | 2026-01-22 | 成都地奥九泓制药厂 | Glp-1受体激动剂化合物的盐、晶型、制备方法及其药物组合物和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138530B2 (en) | 2002-05-28 | 2006-11-21 | 3-Dimensional Pharmaceuticals, Inc. | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| CN102378574B (zh) | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| US8420655B2 (en) * | 2009-12-04 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| CN105980379B (zh) | 2014-12-08 | 2018-09-07 | 江苏恒瑞医药股份有限公司 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| CN112955444B (zh) * | 2019-01-22 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202206429A (zh) * | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| CA3192601A1 (en) | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| US20240083886A1 (en) | 2020-10-13 | 2024-03-14 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4229050A4 (en) | 2020-10-13 | 2024-12-11 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN117222631A (zh) | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| WO2023011539A1 (zh) | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
-
2021
- 2021-09-01 CA CA3188891A patent/CA3188891A1/en active Pending
- 2021-09-01 CN CN202510138614.4A patent/CN119930603A/zh active Pending
- 2021-09-01 CN CN202510139459.8A patent/CN119930604A/zh active Pending
- 2021-09-01 AU AU2021306414A patent/AU2021306414B2/en active Active
- 2021-09-01 CN CN202180050847.9A patent/CN115884969B/zh active Active
- 2021-09-01 KR KR1020237009937A patent/KR20230058660A/ko active Pending
- 2021-09-01 EP EP26153808.6A patent/EP4706757A3/en active Pending
- 2021-09-01 US US18/043,508 patent/US12227499B2/en active Active
- 2021-09-01 CN CN202510139492.0A patent/CN119930605A/zh active Pending
- 2021-09-01 FI FIEP21837580.6T patent/FI4209490T3/fi active
- 2021-09-01 MX MX2023001980A patent/MX2023001980A/es unknown
- 2021-09-01 DK DK21837580.6T patent/DK4209490T3/da active
- 2021-09-01 CN CN202510138725.5A patent/CN119954797A/zh active Pending
- 2021-09-01 WO PCT/CN2021/115915 patent/WO2022007979A1/zh not_active Ceased
- 2021-09-01 JP JP2023512797A patent/JP7812052B2/ja active Active
- 2021-09-01 TW TW110132457A patent/TW202220985A/zh unknown
- 2021-09-01 EP EP21837580.6A patent/EP4209490B1/en active Active
- 2021-09-01 PT PT218375806T patent/PT4209490T/pt unknown
-
2024
- 2024-03-21 US US18/612,631 patent/US12473279B2/en active Active
-
2025
- 2025-01-07 US US19/012,024 patent/US20250282773A1/en active Pending
- 2025-03-26 US US19/091,638 patent/US12459937B2/en active Active
- 2025-12-24 JP JP2025280769A patent/JP2026053592A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250243195A1 (en) | 2025-07-31 |
| KR20230058660A (ko) | 2023-05-03 |
| US20230322756A1 (en) | 2023-10-12 |
| CN119930604A (zh) | 2025-05-06 |
| US20250282773A1 (en) | 2025-09-11 |
| CN119930603A (zh) | 2025-05-06 |
| WO2022007979A1 (zh) | 2022-01-13 |
| CN115884969B (zh) | 2025-01-14 |
| EP4209490B1 (en) | 2026-01-28 |
| US20240246958A1 (en) | 2024-07-25 |
| FI4209490T3 (fi) | 2026-03-17 |
| EP4209490A4 (en) | 2023-11-22 |
| CN115884969A (zh) | 2023-03-31 |
| MX2023001980A (es) | 2023-02-27 |
| EP4706757A2 (en) | 2026-03-11 |
| AU2021306414A1 (en) | 2023-05-04 |
| JP7812052B2 (ja) | 2026-02-09 |
| EP4209490A1 (en) | 2023-07-12 |
| US12473279B2 (en) | 2025-11-18 |
| CN119930605A (zh) | 2025-05-06 |
| JP2026053592A (ja) | 2026-03-25 |
| TW202220985A (zh) | 2022-06-01 |
| CN119954797A (zh) | 2025-05-09 |
| PT4209490T (pt) | 2026-03-27 |
| AU2021306414B2 (en) | 2026-01-29 |
| US12227499B2 (en) | 2025-02-18 |
| JP2023539584A (ja) | 2023-09-15 |
| DK4209490T3 (da) | 2026-02-23 |
| US12459937B2 (en) | 2025-11-04 |
| EP4706757A3 (en) | 2026-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3188891A1 (en) | Fused imidazole derivative, preparation method therefor, and medical use thereof | |
| CN115244056B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN113816948B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| AU2017306605B2 (en) | Nitrogen-containing tricyclic compounds and uses thereof in medicine | |
| CN111107848B (zh) | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 | |
| CN114805336B (zh) | 稠合咪唑类化合物、其制备方法及其在医药上的应用 | |
| EP4361145A1 (en) | Glp-1 receptor agonist and composition and use thereof | |
| EP2956458B1 (en) | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | |
| WO2023086800A1 (en) | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | |
| CA3197220A1 (en) | 2-pyridones as thyroid hormone receptor modulators | |
| JP2024501507A (ja) | ケトヘキソキナーゼ阻害剤及びその用途 | |
| WO2024026483A2 (en) | Cdk2 inhibitors and methods of using the same | |
| HK40090843B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| HK40090843A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN116535396A (zh) | 己酮糖激酶抑制剂及其用途 | |
| CN121729412A (zh) | 作为cdk抑制剂的双环化合物 | |
| HK40082497A (en) | Fused imidazole derivatives, preparation method and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240514 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240807 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240807 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250429 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250828 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250829 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251130 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251130 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260203 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260212 |